Double the Survival: The Week Cancer Treatment Brought Breakthroughs on Two Fronts

The FDA approved Rasonque (daraxonrasib), the first oral RAS inhibitor for metastatic pancreatic adenocarcinoma, a cancer with historically grim outcomes. In the Phase III RASolute trial, patients taking Rasonque survived a median of 13.2 months, nearly double the 6.7 months seen with standard chemotherapy. This is a landmark for a disease where five-year survival rates have long hovered in single digits.

Side effects: While the oral, once-daily dosing is a...